Mark Terry
Boston-based Odyssey Therapeutics completed an oversubscribed $218 million Series A round. The funds will be used to advance multiple programs from its pipeline and its discovery platform.
Mark Terry
Boston-based Odyssey Therapeutics completed an oversubscribed $218 million Series A round. The funds will be used to advance multiple programs from its pipeline and its discovery platform.
Ned Pagliarulo
Gary Glick, a chemist and well-known biotech entrepreneur, has raised more than $200 million to launch the latest company aiming to harness advances in medicinal chemistry to invent new drugs for cancer and inflammatory diseases.
Paul Bonanos
As he built newly launched start-up Odyssey, serial entrepreneur Gary Glick followed a mantra from one of his mentors: “Hire as many people as you can who have made drugs before; they will know how to make drugs, and will make drugs again.”
Staff Writer
Odyssey Therapeutics, a Boston MA-based biotechnology company advancing next generation precision immunomodulators and oncology medicines, raised $218M in Series A funding.